2nd Quarter - Report

WILLIAMS AND JENSEN, PLLC for MERCK & CO INC

Firm
Client
Income
$80,000
Expenses
—

What was lobbied

7 issue areas, each in the filer's own words, with who lobbied on it and where.

Defense DEF

Issues related to pharmaceutical manufacturing and development.

LobbyistCovered position, as disclosed
SUSAN HIRSCHMANN New COS, Rep Van Hilleary and Majority Whip
MATTHEW B HOEKSTRA —
CHERYL LYNN JAEGER New Shrd employee, Ofc of the Speaker & Ofc of VA 07; Sr. Policy Adv, Maj Leader, Rep Cantor; Sr Policy Adv, Rep Whip, Rep Cantor; Sr. Policy Adv, Maj Whip, Rp Blunt; Prof Staff House Committee on E&C; Sr LA to Rep Cox
KARINA LYNCH New Staff, Senate Special Committee on Aging; Staff, Senate Committee on Government Affairs; Senate Committees on Aging and Gov Affairs

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); White House Office; SENATE

Taxation/Internal Revenue Code TAX

Issues related to corporate tax including international tax proposals: Implementation of the Tax Cuts and Jobs Act (P.L. 115-97).

LobbyistCovered position, as disclosed
CHRISTOPHER W HATCHER —
SUSAN HIRSCHMANN COS, Rep Van Hilleary and Majority Whip
CHERYL LYNN JAEGER —
KARINA LYNCH —

Contacted: Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); SENATE; HOUSE OF REPRESENTATIVES; White House Office

Trade (domestic/foreign) TRD

International trade issues and agreements; Monitor pending trade issues. Issues related to pharmaceutical manufacturing and development.

LobbyistCovered position, as disclosed
CHRISTOPHER W HATCHER —
SUSAN HIRSCHMANN New COS, Rep Van Hilleary and Majority Whip
MATTHEW B HOEKSTRA New —
CHERYL LYNN JAEGER Shared employee, Ofc of the Speaker & Ofc of VA 07; Sr Policy Adv, Maj Leader, Rep. Cantor; Sr Policy Adv, Republican Whip, Rep. Cantor; Sr Policy Adv, Majority Whip, Rep. Blunt; Prof Staff House Committee on E & C; Sr LA to Rep. Cox
KARINA LYNCH —

Contacted: White House Office; Food & Drug Administration (FDA); SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Animals ANI

Monitor issues as they relate to animal health . Issues concerning the Animal Drug User Fee Act.

LobbyistCovered position, as disclosed
SCOTT GRAVES Deputy Chief of Staff, Rep Conaway; COS, Rep Farenthold, COS, Rep Conaway; Staff Director, House Ag Committee
CHERYL LYNN JAEGER Shrd employee, Ofc of the Speaker & Ofc of VA 7; Sr Plicy Adv, Maj Leader, Rep Cantor; Sr. Policy Adv, Rep Whip, Rep Cantor; Sr. Policy Adv, Maj Whip, Rep Blunt; Prof Staff House Committee on E&C; Sr LA to Rep Cox
KARINA LYNCH Staff, Senate Special Committee on Aging; Staff, Senate Committee on Government Affairs; Senate Committees on Aging and Gov Affairs.
MATTHEW S VALESKO —

Contacted: White House Office; SENATE; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Health Issues HCR

Drug safety; Congressional oversight issues; Issues related to vaccines and drug pricing; Drug pricing under 340B program; General education about FDA approval policies. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136.

LobbyistCovered position, as disclosed
SUSAN HIRSCHMANN —
CHERYL LYNN JAEGER —
KARINA LYNCH —

Contacted: SENATE; White House Office; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS)

Bills named: H.R. 3 (116th), H.R. 748 (116th), S. 2543 (116th), H.R. 604 (116th)

Medicare/Medicaid MMM

Payment policies for Part B prescription drugs; Rebates and co-pays for Medicare Part D drug benefits; Possible revisions in structure and operation of Medicare and Medicaid drug policies. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136.

LobbyistCovered position, as disclosed
SUSAN HIRSCHMANN —
MATTHEW B HOEKSTRA —
CHERYL LYNN JAEGER Shared employee, Ofc of the Speaker and Ofc of VA 7th; Sr Policy Advisor, Majority Leader, Rep. Eric Cantor; Sr. Advisor, Majority Whip, Rep Roy Blunt; Prof Staff House Committee on E&C; Sr LA to Rep. Christopher Cox
KARINA LYNCH —

Contacted: White House Office; Health & Human Services, Dept of (HHS); SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA)

Bills named: H.R. 604 (116th), H.R. 3 (116th), H.R. 748 (116th), S. 2543 (116th)

Budget/Appropriations BUD

Policies impacting Medicare Part D. Drug Development and Public Health Preparedness. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136.

LobbyistCovered position, as disclosed
SUSAN HIRSCHMANN COS, Rep Van Hilleary and Majority Whip
MATTHEW B HOEKSTRA —
CHERYL LYNN JAEGER Shrd employee, Ofc of the Speaker & Ofc of VA 7;Sr policy adv, Maj Leader, Rep Cantor; Sr. Policy Adv, Rep Whip, Rep Cantor; Sr. Policy Adv, Maj Whip, Rep Blunt; Prof Staff House Committee on E&C; Sr. LA to Rep Cox
KARINA LYNCH Staff, Senate Special Committee on Aging; Staff, Senate Committee on Government Affairs; Senate Committees on Aging and Government Affairs

Contacted: Food & Drug Administration (FDA); White House Office; SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Bills named: H.R. 604 (116th), H.R. 748 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.